CA057-001

Name No. For Patients with Purpose
CA057-001 CA057-001

Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.

To determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.

CA058-1019

Name No. For Patients with Purpose
CA058-1019 CA058-1019

Relapsed or refractory multiple myeloma who have already had 2 to 3 lines of MM therapy, including a drug called lenalidomide and a drug from a class called anti-CD38 antibodies.

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).


MajesTEC-4

Name No. For Patients with Purpose
MajesTEC-4 23-21

Newly diagnosed multiple myeloma

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.


AFFIRM-AL

Name No. For Patients with Purpose
AFFIRM-AL 22-13

The target population for this study are Mayo Stage IV AL amyloid patients

This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients


Isa-RVD

Name No. For Patients with Purpose
Isa-RVD 19-34

The target population for this study are patients with newly diagnosed multiple myeloma for high dose therapy and autologous stem cell transplant. Patients will have a confirmed diagnosis of multiple myeloma, based on standard IMWG criteria.

This study is a Phase II, multi-centre, single-arm, open-label study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in patients with newly diagnosed multiple myeloma